Results for tag: "Iron Deficiency Injectable"

The iron deficiency injectable market falls under the broader category of infusions and injectables, which are routes of administration for various medications and treatments. Iron deficiency injectables are specifically designed to address iron-deficiency anemia and related conditions, where oral iron supplements may not be sufficient or feasible. Such deficiencies may arise from numerous medical circumstances including chronic illnesses, gastrointestinal disorders, or increased iron requirements. These injectables are commonly used in medical facilities and are administered intravenously or intramuscularly, providing a direct and rapid increase in iron levels. The convenience of less frequent dosing compared to oral supplements, as well as the quick response in replenishing iron stores, makes them a preferred option for both providers and patients in certain clinical situations. Several pharmaceutical and healthcare companies are active in the iron deficiency injectable market. Some of these entities include Vifor Pharma, which markets Ferinject (ferric carboxymaltose), Daiichi Sankyo, the company behind Injectafer (ferric carboxymaltose), and Pharmacosmos with its product Monofer (iron isomaltoside 1000). Other notable firms include Sanofi, which provides Ferrlecit (sodium ferric gluconate), and American Regent, which manufactures Venofer (iron sucrose). These companies, among others, engage in the research, development, and commercialization of iron therapy solutions aimed at treating patients with iron deficiency anemia. Show Less Read more